News & Views
Cyprotex Adds to Toxicology Services
Oct 05 2010
Cyprotex PLC, a preclinical ADME Tox services company has launched a new in vitro toxicology service, branded as Cyprotox®. Supporting the new service is an additional 90 square metres of laboratory space at Cyprotex’s Macclesfield, UK facility, which offers multi-parametric automated fluorescent imaging and cellular analysis. The new facility utilises high content screening (HCS) technology and a range of other services to assess toxicity to determine multiparametric indicators of toxicity. HCS is a recent breakthrough for early toxicology assessment. It has been extensively validated, and is now being adopted throughout the pharmaceutical industry.
Dr Anthony Baxter, Chief Executive Officer, said: “Drug toxicity, and drug-induced liver injury in particular, is a major reason for failures in clinical trials and for the withdrawal of previously approved drugs from the market. Toxicity is the most costly problem in drug development today. Identifying potential liabilities at an early stage in drug discovery decreases the likelihood of latestage failures, and promises to produce the same magnitude of drug development efficiency improvements that preclinical ADME has provided. Cyprotex’s new toxicology facility complements our existing ADME business, and it aligns the capabilities of our UK facility with those of Apredica’s US facility, which Cyprotex acquired earlier this month.”
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan